| Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study JS Abramson, ML Palomba, LI Gordon, MA Lunning, M Wang, J Arnason, ... The Lancet 396 (10254), 839-852, 2020 | 2060 | 2020 |
| Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade … TE Witzig, LI Gordon, F Cabanillas, MS Czuczman, C Emmanouilides, ... Journal of clinical oncology 20 (10), 2453-2463, 2002 | 1606 | 2002 |
| Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy MS Czuczman, AJ Grillo-Lopez, CA White, M Saleh, L Gordon, ... Journal of Clinical Oncology 17 (1), 268-268, 1999 | 1231 | 1999 |
| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 1189 | 2022 |
| Genetic and functional drivers of diffuse large B cell lymphoma A Reddy, J Zhang, NS Davis, AB Moffitt, CL Love, A Waldrop, S Leppa, ... Cell 171 (2), 481-494. e15, 2017 | 1101 | 2017 |
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project KR Carson, AM Evens, EA Richey, TM Habermann, D Focosi, JF Seymour, ... Blood, The Journal of the American Society of Hematology 113 (20), 4834-4840, 2009 | 1068 | 2009 |
| An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era Z Zhou, LH Sehn, AW Rademaker, LI Gordon, AS LaCasce, ... Blood, The Journal of the American Society of Hematology 123 (6), 837-842, 2014 | 1041 | 2014 |
| Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis SA Weitzman, LI Gordon Blood 76 (4), 655-663, 1990 | 986 | 1990 |
| Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma TE Witzig, IW Flinn, LI Gordon, C Emmanouilides, MS Czuczman, ... Journal of clinical oncology 20 (15), 3262-3269, 2002 | 891 | 2002 |
| Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma TE Witzig, CA White, GA Wiseman, LI Gordon, C Emmanouilides, ... Journal of clinical oncology 17 (12), 3793-3803, 1999 | 745 | 1999 |
| The genetic landscape of mutations in Burkitt lymphoma C Love, Z Sun, D Jima, G Li, J Zhang, R Miles, KL Richards, CH Dunphy, ... Nature genetics 44 (12), 1321-1325, 2012 | 704 | 2012 |
| Genetic heterogeneity of diffuse large B-cell lymphoma J Zhang, V Grubor, CL Love, A Banerjee, KL Richards, PA Mieczkowski, ... Proceedings of the National Academy of Sciences 110 (4), 1398-1403, 2013 | 650 | 2013 |
| Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results … P Armand, A Nagler, EA Weller, SM Devine, DE Avigan, YB Chen, ... Journal of clinical oncology 31 (33), 4199-4206, 2013 | 557 | 2013 |
| Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy BD Cheson, S Ansell, L Schwartz, LI Gordon, R Advani, HA Jacene, ... Blood, The Journal of the American Society of Hematology 128 (21), 2489-2496, 2016 | 528 | 2016 |
| Non-Hodgkin’s lymphomas AD Zelenetz, JS Abramson, RH Advani, CB Andreadis, JC Byrd, ... Journal of the National Comprehensive Cancer Network 8 (3), 288-334, 2010 | 458 | 2010 |
| Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma LI Gordon, D Harrington, J Andersen, J Colgan, J Glick, R Neiman, ... New England Journal of Medicine 327 (19), 1342-1349, 1992 | 429 | 1992 |
| Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial GA Wiseman, LI Gordon, PS Multani, TE Witzig, S Spies, NL Bartlett, ... Blood, The Journal of the American Society of Hematology 99 (12), 4336-4342, 2002 | 385 | 2002 |
| Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma TE Witzig, CA White, LI Gordon, GA Wiseman, C Emmanouilides, ... Journal of Clinical Oncology 21 (7), 1263-1270, 2003 | 381 | 2003 |
| Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era AM Evens, KA David, I Helenowski, B Nelson, D Kaufman, SM Kircher, ... Journal of Clinical Oncology 28 (6), 1038-1046, 2010 | 358 | 2010 |
| Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated … LI Gordon, F Hong, RI Fisher, NL Bartlett, JM Connors, RD Gascoyne, ... Journal of Clinical Oncology 31 (6), 684-691, 2013 | 352 | 2013 |
